Analysts Expect Allogene Therapeutics Inc (NASDAQ:ALLO) Will Announce Earnings of -$0.47 Per Share

Brokerages expect Allogene Therapeutics Inc (NASDAQ:ALLO) to announce earnings of ($0.47) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Allogene Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.37) and the lowest estimate coming in at ($0.54). The business is scheduled to issue its next quarterly earnings report on Tuesday, August 6th.

On average, analysts expect that Allogene Therapeutics will report full-year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.10) to ($1.45). For the next year, analysts anticipate that the business will report earnings of ($2.37) per share, with EPS estimates ranging from ($2.89) to ($1.71). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow Allogene Therapeutics.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08.

ALLO has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Gerdau from a “sell” rating to a “hold” rating in a research note on Monday, May 13th. Piper Jaffray Companies upgraded shares of F5 Networks from an “underweight” rating to a “neutral” rating and lifted their price target for the stock from $157.00 to $163.00 in a research note on Friday, March 29th. Stifel Nicolaus set a $154.00 price objective on shares of argenx and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Roth Capital began coverage on shares of Allogene Therapeutics in a report on Wednesday, June 5th. They issued a “neutral” rating and a $26.00 price objective on the stock. Finally, Oppenheimer began coverage on shares of Allogene Therapeutics in a report on Friday, May 3rd. They issued an “outperform” rating and a $45.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Allogene Therapeutics currently has an average rating of “Buy” and an average price target of $35.44.

In other Allogene Therapeutics news, insider Alison Moore sold 48,828 shares of Allogene Therapeutics stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $26.76, for a total transaction of $1,306,637.28. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Group Holdings (Sbs) Advis Tpg sold 1,918,755 shares of Allogene Therapeutics stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $29.38, for a total transaction of $56,373,021.90. The disclosure for this sale can be found here. 36.50% of the stock is owned by insiders.

Large investors have recently modified their holdings of the business. Barclays PLC purchased a new position in Allogene Therapeutics during the fourth quarter valued at approximately $27,000. Legal & General Group Plc purchased a new position in Allogene Therapeutics during the fourth quarter valued at approximately $89,000. Partner Investment Management L.P. purchased a new position in shares of Allogene Therapeutics in the fourth quarter worth $135,000. NumerixS Investment Technologies Inc purchased a new position in shares of Allogene Therapeutics in the first quarter worth $136,000. Finally, Citigroup Inc. purchased a new position in shares of Allogene Therapeutics in the fourth quarter worth $152,000. 53.47% of the stock is currently owned by institutional investors and hedge funds.

Shares of ALLO stock traded down $0.21 during trading hours on Friday, reaching $26.40. The company had a trading volume of 320,634 shares, compared to its average volume of 517,616. The business has a fifty day moving average of $26.99. Allogene Therapeutics has a one year low of $21.67 and a one year high of $35.55. The firm has a market capitalization of $3.23 billion and a price-to-earnings ratio of -4.01. The company has a current ratio of 17.48, a quick ratio of 17.48 and a debt-to-equity ratio of 0.05.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma.

Featured Article: Does the discount rate affect the economy?

Get a free copy of the Zacks research report on Allogene Therapeutics (ALLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.